David Ian Paterson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Ian Paterson has a total of 598 co-authors. Here are the top co-authors by number of shared publications:
- Richard B. Thompson
Department of Radiology and Diagnostic Imaging University of Alberta Edmonton Alberta Canada
32 shared publications Mark J. Haykowsky
College of Health Sciences, University of Alberta, Edmonton, AB, Canada
21 shared publicationsEdith Pituskin
College of Health Sciences, University of Alberta, Edmonton, AB, Canada
14 shared publicationsGavin Y. Oudit
Department of Medicine, University of Alberta, Edmonton, AB, Canada
13 shared publications- Gavin Y. Oudit
Department of Medicine, University of Alberta, Edmonton, Canada
13 shared publications Kelvin Chow
Mazankowski Alberta Heart Institute, 11220 83 Avenue NW, Edmonton, Alberta, Canada, T6G 2B7
13 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Elsevier in JACC: Case Reports
Extensive Native Aortic Valve Infiltration and Early Bioprosthetic Valve Degeneration in Low-Grade Chronic Lymphocytic Leukemia
- 13 November 2026
- Published by Elsevier in JACC: Case Reports
Open AccessExtensive Native Aortic Valve Infiltration and Early Bioprosthetic Valve Degeneration in Low-Grade Chronic Lymphocytic Leukemia
- Open Access
- 26 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
Reply: Myocardial oedema in takotsubo syndrome: a still not fully characterized variable
- 26 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
Open AccessReply: Myocardial oedema in takotsubo syndrome: a still not fully characterized variable
- 23 October 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 64, 102976
Reply: Temporal associations of myocardial edema, blood flow, and left ventricular contractility in Takotsubo syndrome
- 23 October 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 64, 102976
Reply: Temporal associations of myocardial edema, blood flow, and left ventricular contractility in Takotsubo syndrome
- Open Access
- 13 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (4)
Frequency of late gadolinium enhancement-negative cardiac magnetic resonance imaging at initial presentation with metabolically active treatment-naïve cardiac sarcoidosis
Aims: The 2024 American Heart Association statement recommends fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) for patients with high clinical suspicion of cardiac sarcoidosis even without late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR), but this recommendation has been challenged. We determined the frequency of LGE-negative CMR at first presentation of clinically manifest, metabolically active, treatment-naïve cardiac sarcoidosis. Methods and results: In this single-centre sub-study of the prospective Cardiac Sarcoidosis Multi-Center Prospective Cohort Study, we analysed 46 consecutive treatment-naïve patients with de novo clinically manifest cardiac sarcoidosis and core-laboratory-defined abnormal cardiac and extracardiac FDG uptake, imaged within a 6-month interval, before immunosuppression. Four of 46 patients had no LGE on CMR (8.7%; exact 95% CI, 2.4–20.8%). All four presented with advanced atrioventricular conduction disease and none had ventricular tachycardia; three of four started immunosuppressive therapy. Compared with LGE-positive patients, LGE-negative patients had preserved left ventricular ejection fraction and lower cardiac inflammatory burden (left ventricular maximum standardized uptake value 3.9 ± 0.9 vs. 9.6 ± 5.2; P = 0.037). Conclusion: An LGE-negative phenotype can occur in clinically relevant, treatment-naïve, FDG-avid cardiac sarcoidosis. These findings suggest considering FDG-PET in selected patients with high clinical suspicion of cardiac sarcoidosis, even when CMR shows no LGE.
- 13 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (4)
Open AccessFrequency of late gadolinium enhancement-negative cardiac magnetic resonance imaging at initial presentation with metabolically active treatment-naïve cardiac sarcoidosis
Aims: The 2024 American Heart Association statement recommends fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) for patients with high clinical suspicion of cardiac sarcoidosis even without late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR), but this recommendation has been challenged. We determined the frequency of LGE-negative CMR at first presentation of clinically manifest, metabolically active, treatment-naïve cardiac sarcoidosis. Methods and results: In this single-centre sub-study of the prospective Cardiac Sarcoidosis Multi-Center Prospective Cohort Study, we analysed 46 consecutive treatment-naïve patients with de novo clinically manifest cardiac sarcoidosis and core-laboratory-defined abnormal cardiac and extracardiac FDG uptake, imaged within a 6-month interval, before immunosuppression. Four of 46 patients had no LGE on CMR (8.7%; exact 95% CI, 2.4–20.8%). All four presented with advanced atrioventricular conduction disease and none had ventricular tachycardia; three of four started immunosuppressive therapy. Compared with LGE-positive patients, LGE-negative patients had preserved left ventricular ejection fraction and lower cardiac inflammatory burden (left ventricular maximum standardized uptake value 3.9 ± 0.9 vs. 9.6 ± 5.2; P = 0.037). Conclusion: An LGE-negative phenotype can occur in clinically relevant, treatment-naïve, FDG-avid cardiac sarcoidosis. These findings suggest considering FDG-PET in selected patients with high clinical suspicion of cardiac sarcoidosis, even when CMR shows no LGE.
- Open Access
- 7 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (11) , 1955-1966
Prognostic value of cardiac magnetic resonance global T2 mapping in patients with takotsubo syndrome
Aims: Myocardial oedema is a hallmark of takotsubo syndrome (TTS). Cardiac magnetic resonance (CMR) T2 mapping quantifies myocardial oedema, but its prognostic value in TTS is unclear. We evaluated the association between CMR-derived global myocardial T2 and major adverse cardiovascular and cerebrovascular events (MACE). Methods and results: We retrospectively identified consecutive TTS patients undergoing CMR with tissue mapping within 30 days of admission. Imaging was re-analysed, blinded to clinical data. The primary endpoint was MACE (all-cause death, heart failure hospitalization, recurrent TTS, stroke, or transient ischaemic attack). Time-dependent receiver operating characteristic (ROC) analysis derived a T2 threshold. Prespecified covariates were summarized by ridge-penalized Cox into a single linear predictor for adjustment. A Firth-penalized Cox model tested robustness. Among 110 patients (median age 68 years; 91% women), median global T2 was 56 ms (IQR 53–60), and 17 (15.5%) experienced MACE over a median follow-up of 763 days (IQR 525–1357). T2 ≥ 63 ms predicted 1-year MACE (AUC 0.671, sensitivity 56%, specificity 89%) and separated Kaplan–Meier curves (log-rank P = 0.003). In ridge-penalized Cox models, each 5 ms increase in global T2 was associated with MACE (HR 1.40, 95% CI 1.06–1.87; P = 0.020). This association was also observed after adjustment in the Firth-penalized model (HR 1.70, 95% CI 1.20–2.40; P = 0.004). An internally derived threshold of T2 ≥ 63 ms was also associated with MACE but showed modest 1-year discrimination (AUC 0.671). Conclusion: Global myocardial T2 may provide incremental prognostic information beyond prespecified clinical and imaging indices in TTS and refine risk stratification.
- 7 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (11) , 1955-1966
Open AccessPrognostic value of cardiac magnetic resonance global T2 mapping in patients with takotsubo syndrome
Aims: Myocardial oedema is a hallmark of takotsubo syndrome (TTS). Cardiac magnetic resonance (CMR) T2 mapping quantifies myocardial oedema, but its prognostic value in TTS is unclear. We evaluated the association between CMR-derived global myocardial T2 and major adverse cardiovascular and cerebrovascular events (MACE). Methods and results: We retrospectively identified consecutive TTS patients undergoing CMR with tissue mapping within 30 days of admission. Imaging was re-analysed, blinded to clinical data. The primary endpoint was MACE (all-cause death, heart failure hospitalization, recurrent TTS, stroke, or transient ischaemic attack). Time-dependent receiver operating characteristic (ROC) analysis derived a T2 threshold. Prespecified covariates were summarized by ridge-penalized Cox into a single linear predictor for adjustment. A Firth-penalized Cox model tested robustness. Among 110 patients (median age 68 years; 91% women), median global T2 was 56 ms (IQR 53–60), and 17 (15.5%) experienced MACE over a median follow-up of 763 days (IQR 525–1357). T2 ≥ 63 ms predicted 1-year MACE (AUC 0.671, sensitivity 56%, specificity 89%) and separated Kaplan–Meier curves (log-rank P = 0.003). In ridge-penalized Cox models, each 5 ms increase in global T2 was associated with MACE (HR 1.40, 95% CI 1.06–1.87; P = 0.020). This association was also observed after adjustment in the Firth-penalized model (HR 1.70, 95% CI 1.20–2.40; P = 0.004). An internally derived threshold of T2 ≥ 63 ms was also associated with MACE but showed modest 1-year discrimination (AUC 0.671). Conclusion: Global myocardial T2 may provide incremental prognostic information beyond prespecified clinical and imaging indices in TTS and refine risk stratification.
- Open Access
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Goal-directed vs self-directed Valsalva manoeuvre to improve right-to-left shunt detection: the BUBBLE trial
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Open AccessGoal-directed vs self-directed Valsalva manoeuvre to improve right-to-left shunt detection: the BUBBLE trial
- Open Access
- 29 August 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 63
Myocardial edema, blood flow, and contractility in Takotsubo syndrome: Comparative evaluation with cardiac magnetic resonance and positron emission tomography
- 29 August 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 63
Open AccessMyocardial edema, blood flow, and contractility in Takotsubo syndrome: Comparative evaluation with cardiac magnetic resonance and positron emission tomography
- Open Access
- 22 May 2026
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (5) , S101-S104
A Primer on Rare Cardiac Diseases
- 22 May 2026
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (5) , S101-S104
Open AccessA Primer on Rare Cardiac Diseases
- 1 May 2026
- Vol. 42 (5S) , S101-S104
A Primer on Rare Cardiac Diseases.
- Open Access
- 13 April 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (19) , 107834
Epicardial Fat Necrosis as a Rare Cause of Chest Pain
- 13 April 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (19) , 107834
Open AccessEpicardial Fat Necrosis as a Rare Cause of Chest Pain